Global MRSA Drugs Market 2016-2020
SKU ID :TNV-10279642 | Published Date: 27-Jul-2016 | No. of pages: 79Description
About Methicillin-Resistant Staphylococcus aureus (MRSA)
MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.
Technavio’s analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Allergan
• Merck & Co.
• Pfizer
• Theravance Biopharma
Other prominent vendors
• Absynth Biologics
• AmpliPhi Biosciences Corporation
• AstraZeneca
• Basilea Pharmaceutica
• Baxter International
• Cellceutix
• Cempra Inc.
• CrystalGenomics
• Debiopharm Group
• Galapagos NV
• GSK
• KYORIN Pharmaceutical
• Lytix Biopharma
• Melinta Therapeutics
• Nabriva Therapeutics
• NovaDigm Therapeutics
• Paratek Pharmaceuticals
• R-Pharm
• Savara Pharmaceuticals
• Sealife Pharma
• Sequella Inc.
• The Medicines Company
• XBiotech
Market driver
• Special regulatory designations
• For a full, detailed list, view our report
Market challenge
• Development of drug-resistant strains
• For a full, detailed list, view our report
Market trend
• Strategic alliances and M&A
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.
Technavio’s analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Allergan
• Merck & Co.
• Pfizer
• Theravance Biopharma
Other prominent vendors
• Absynth Biologics
• AmpliPhi Biosciences Corporation
• AstraZeneca
• Basilea Pharmaceutica
• Baxter International
• Cellceutix
• Cempra Inc.
• CrystalGenomics
• Debiopharm Group
• Galapagos NV
• GSK
• KYORIN Pharmaceutical
• Lytix Biopharma
• Melinta Therapeutics
• Nabriva Therapeutics
• NovaDigm Therapeutics
• Paratek Pharmaceuticals
• R-Pharm
• Savara Pharmaceuticals
• Sealife Pharma
• Sequella Inc.
• The Medicines Company
• XBiotech
Market driver
• Special regulatory designations
• For a full, detailed list, view our report
Market challenge
• Development of drug-resistant strains
• For a full, detailed list, view our report
Market trend
• Strategic alliances and M&A
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
TOC
Tables & Figures
Companies
- PRICE
-
$2500$4000Buy Now